Prospective Source of α-Amylase Inhibitor and Antioxidant from Non-Dairy Kefir Developed from a Combination of Soybean and Jack Bean

Abstract

Diabetes mellitus can be controlled by inhibiting α-amylase activity in the digestive tract and increasing antioxidant intake. The presence of α-amylase inhibitors will delay the breakdown of carbohydrates, thereby slowing down glucose absorption and helping control blood glucose concentrations. Meanwhile, antioxidant intake can help prevent diabetes complications through free radical scavenging mechanisms. Inhibitor diabetes-related enzyme compounds have also been reported to be contained in soybean and jackbean commodities. The aim of this study was to explore the potential of non-dairy kefir made from soybeans and jack beans as a source of α-amylase inhibitors and antioxidants through in vitro assay. These results of the study successfully identified α-amylase inhibitor activity of 58.10-60.92% and antioxidants of 52.81% (DPPH) and 47.12% (ABTS) from mixed soybean and jackbean kefir. The preferred organoleptic profile is relatively acceptable. The bioactivity of α-amylase inhibitors and antioxidants was confirmed in vitro in non-dairy kefir, this could be the basis for molecular isolation or in vivo research.